Tixagevimab/cilgavimab reduced COVID-19 risk: real-time meta-analysis of 19 studies (Version 32)

Significantly lower risk is seen for mortality, hospitalization, and cases. 9 studies from 9 independent teams in 3 countries show significant benefit.

Meta-analysis using the most serious outcome reported shows 34% [11‑51%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies.

Results are robust—in worst case exclusion sensitivity analysis 6 of 19 studies must be excluded before statistical significance is lost.

Control Tixagevimab/c..Tixagev../c..

Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, and BQ.1.11, BA.5, BA.2.75, XBB2,3, XBB.1.53, XBB.1.9.13, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.14. US EUA has been revoked. mAb use may create new variants that spread globally5-7, and may be associated with increased risk of autoimmune disease8, prolonged viral loads, clinical deterioration, and immune escape6,9-13.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.

Soeroto et al. present another meta-analysis for tixagevimab/cilgavimab, showing significant improvements for mortality, hospitalization, severity, and cases.